Alzheimer's Disease Modifiers
Alzheimer's Disease
Pre-clinicalActive
Key Facts
About AfaSci
AfaSci is a unique, self-sustaining biotech holding group with three synergistic business lines: therapeutic development (AfaSci Therapeutics), preclinical contract research services (AfaSci Research Laboratories), and research instrumentation (AfaSci Instruments). Its lead asset, AFA-281, is a Phase I-completed, novel dual-mechanism small molecule for chronic pain and epilepsy, protected by composition of matter patents in 16 countries. The company is currently seeking investment and partnerships to advance AFA-281 into Phase II proof-of-concept studies, with a potential exit via M&A upon successful trial results.
View full company profileTherapeutic Areas
Other Alzheimer's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| NUZ-001 | Neurizon Therapeutics | Preclinical |
| ALZN002 | Alzamend Neuro | Preclinical |
| P021 | Phanes Biotech | Preclinical |
| PB43D | Phanes Biotech | Preclinical |
| UB-311 | Vaxxinity | Phase 2 |
| Lecanemab | BioArctic | Launched |
| BAN2401 | BioArctic | Preclinical |
| Undisclosed Programs | johnson-and-johnson-innovative-medicine | Pipeline |
| MK-6240 (florquinitau) | Lantheus Medical Imaging | Regulatory Filing |
| NAV-4694 (flutafuranol) | Lantheus Medical Imaging | Phase 3 |
| LNTH-2620/PI-2620 | Lantheus Medical Imaging | Phase 3 |
| itMSCs | Stemedica Cell Technologies | Clinical Development |